RxDoctor Payments Data

David Shadid, DO

Psychiatry · Tulsa, OKNPI 1508934126

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 136 payments — averaging $13.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$247
  • Sunovion Pharmaceuticals Inc.$219
  • Otsuka America Pharmaceutical, Inc.$178
  • Shire North American Group Inc$165
  • Rhodes Pharmaceuticals L.p.$165
  • Takeda Pharmaceuticals U.S.A., Inc.$159
  • plus $637 from 12 others

What the payments were for

  • Food & beverage$1,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,770 in reported general payments places this provider in the 75th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$12,417
Medicare patients
50
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate45$17,386
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine186$8,508
Methylphenidate ErMethylphenidate Hcl43$4,621
Lisdexamfetamine Dimesylate23$2,829
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine56$2,517
Duloxetine Hcl49$2,015
Vilazodone Hcl19$1,469
Lamotrigine79$1,150
Bupropion XlBupropion Hcl57$1,048
Atomoxetine Hcl17$904
Eszopiclone14$674
Methylphenidate Hcl23$626
Alprazolam92$503
Fluoxetine Hcl40$495
Mirtazapine30$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$159$17,38645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →